Explainer: RSV may not quite have the name recognition that influenza and Covid do, but it's actually causing more winter ...

Dual long‑acting antibodies that lock RSV’s fusion protein from two sides protect against RSV A and B and prevent resistance, offering durable protection.

Final trial results add to evidence supporting use in tots who remain at increased risk ...

Future therapies for respiratory syncytial virus (RSV) must target both the virus and the immune response to ensure babies ...

Researchers suggest targeting neutrophil-driven inflammatory pathways may be critical for reducing pathology in infant RSV ...

International evidence has shown immunisation programmes reduces hospitalisations from respiratory syncytial virus by up to ...

Viral infections that attack the lungs are among the leading reasons infants are hospitalized. A new treatment may offer protection against these infections that is as effective and safe as existing ...

Adults aged 18 to 64 years with high-risk conditions demonstrate higher rates of RSV-related LRTD than those without these conditions.

The FDA has called out Sanofi’s promotion of respiratory syncytial virus (RSV) antibody Beyfortus in a new untitled letter, taking issue with the company’s characterization of the med as a general | ...

While the climate pattern does not directly cause illness, it can increase the risk of mosquito-borne diseases and aggravate ...

Many older Australians know RSV can be serious, but new research suggests many underestimate their own risk as cases continue ...

Respiratory viral codetections are common in young children with RSV and are not associated with worsened clinical course and increased health care resource use.